A review of empirical evidence of somatic treatment options for the MI/DD population.
This article reviews recent evidence in the literature for the use of psychotropic and other somatic treatments in the management of patients with mental retardation (MR). The search methodology included peer-reviewed English language publications in PubMed and PsychINFO with the words Mental Retardation, Intellectual Disability, Developmental Disability and Mental Disorders/Drug Therapy or Antipsychotic medications, Psychiatric Somatic therapies, Neuroleptic Drugs, Antidepressants and Electroconvulsive Therapy from 1998 to 2008. The review revealed few randomized controlled trials on the medications frequently prescribed for patients with MR. Three RCTs of Risperidone in children, one combining adults and children and one with adults only are discussed. There was one RCT involving Quetiapine and one on Citalopram. There is little evidence to support the scope of psychotropic medication use in the MR population though the field is advancing. The contribution of psychiatric illness to challenging behaviors is not systematically addressed in the literature.
Ulzen
Thaddeus P
TP
Department of Psychiatry and Behavioral Medicine, College of Community Health Sciences, University of Alabama School of Medicine, Tuscaloosa Campus, 850 5th Avenue East, Tuscaloosa, AL 35401, USA. tulzen@cchs.ua.edu
Powers
Richard E
RE
D001521:Behavior Therapy / Q000379:methods*; D002648:Child; D003131:Combined Modality Therapy; D002658:Developmental Disabilities / Q000453:epidemiology*; D004358:Drug Therapy / Q000379:methods*; D006801:Humans; D008607:Intellectual Disability / Q000453:epidemiology* / Q000628:therapy*; D001523:Mental Disorders / Q000453:epidemiology* / Q000628:therapy*